SCLC's Treatment Arsenal Improving

Area of Science:

• Oncology
• Immunotherapy

Background:

• Small cell lung cancer (SCLC) treatment has seen limited progress over decades.
• There is a critical need for novel therapeutic strategies in SCLC.

Purpose of the Study:

• To evaluate the long-term efficacy of immune checkpoint inhibition in SCLC.
• To explore emerging therapeutic options for second- or later-line treatment in SCLC.

Main Methods:

• Analysis of long-term data from the KEYNOTE-604 trial.
• Review of emerging clinical trial data for bispecific T-cell engagers and combination therapies.

Main Results:

• Long-term data from KEYNOTE-604 demonstrate durable benefit with upfront immune checkpoint inhibition.
• Bispecific T-cell engagers and other combination therapies show potential in later-line settings.

Conclusions:

• Upfront immune checkpoint inhibition is a supported strategy for durable benefit in SCLC.
• Novel agents like bispecific T-cell engagers offer new avenues for patients requiring second- or later-line SCLC therapy.